Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001193125-26-449910
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.07M | $266.00K | — | — |
| Net Income | -$3.65M | -$2.91M | -$2.47M | -$1.42M |
| EPS Diluted |
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.08 |
| -$0.10 |
| -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gross margin was approximately 82% for the three months ended September 30, 2026, compared to approximately 80% for the prior-year period.¶1
Net loss per share was $0.08 for the three months ended September 30, 2026, the same as the net loss per share for the three months ended September 30, 2025.¶2
Cash and cash equivalents were approximately $10.4 million as of September 30, 2026, up from approximately $9.5 million as of June 30, 2026, driven by $3.5 million received from warrant exercises.¶3
RenovoRx ended the third quarter of 2026 with 26 active commercial cancer center customers and maintained full-year 2026 revenue guidance of $3.75 million to $4.25 million.¶4¶5